Freezing plus immunotherapy for advanced stomach cancer
Part of Cancer, Digestive system clinical trials.
This study tests a treatment that freezes the tumor (cryoablation) combined with an immunotherapy drug (PD-1 inhibitor) for people with advanced stomach cancer. It aims to see if this combination helps keep the cancer under control longer than standard therapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced stomach cancer (stage IV) that cannot be removed with surgery or you cannot have surgery.
- You are 18 years or older.
- Your cancer type is adenocarcinoma or neuroendocrine tumor.
- Your doctor expects you to live more than 3 months.
- Your main tumor is 6 cm or smaller.
- Your organs (liver, kidneys, blood, and clotting) are working well enough.
- You have not had certain infections (like HIV, active hepatitis B or C, or tuberculosis).
- You have not taken blood thinners or antiplatelet drugs in the past week.
- You are not pregnant or breastfeeding, and if you could become pregnant, you agree to use birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach that combines freezing the tumor from inside the stomach with an immunotherapy drug that helps your immune system fight cancer. It is for people with advanced stomach cancer that has not responded to previous chemotherapy.
This trial tests a combination of an immunotherapy drug (sintilimab) and two chemotherapy drugs (nab-paclitaxel and tegafur) as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps people live longer and controls the cancer better.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a combination of fecal microbiota transplant (FMT), chemotherapy (SOX), and an immunotherapy drug (Sintilimab) as a first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This study tests whether giving treatment based on the specific markers of your tumor can better control advanced stomach cancer. The goal is to match the right therapy to each person's cancer.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.